Adicet Bio, Inc. Relocates Principal Executive Offices

Ticker: ACET · Form: 8-K · Filed: Oct 7, 2025 · CIK: 1720580

Adicet Bio, Inc. 8-K Filing Summary
FieldDetail
CompanyAdicet Bio, Inc. (ACET)
Form Type8-K
Filed DateOct 7, 2025
Risk Levellow
Pages6
Reading Time8 min
Key Dollar Amounts$0.0001
Sentimentneutral

Sentiment: neutral

Topics: corporate-action, address-change

TL;DR

Adicet Bio moved its HQ to Boston, MA on Oct 7, 2025.

AI Summary

On October 7, 2025, Adicet Bio, Inc. filed an 8-K report. The filing indicates a change in the company's principal executive offices to 131 Dartmouth Street, Floor 3, Boston, Massachusetts, 02116. This move is effective as of October 7, 2025.

Why It Matters

A change in principal executive offices can signal operational shifts or growth for a company. Investors should monitor if this move is associated with other strategic changes.

Risk Assessment

Risk Level: low — This filing solely reports a change in the company's address and does not involve financial transactions or significant operational changes.

Key Players & Entities

  • Adicet Bio, Inc. (company) — Registrant
  • October 07, 2025 (date) — Date of earliest event reported
  • 131 Dartmouth Street, Floor 3, Boston, Massachusetts, 02116 (location) — New Principal Executive Offices

FAQ

What is the new address for Adicet Bio, Inc.'s principal executive offices?

The new address is 131 Dartmouth Street, Floor 3, Boston, Massachusetts, 02116.

When was the change of address effective?

The change of address was effective as of October 07, 2025.

Is this filing related to any financial transactions?

No, this filing (Form 8-K) is primarily to report the change in principal executive offices and does not detail financial transactions.

What was Adicet Bio, Inc.'s former company name?

Adicet Bio, Inc.'s former company name was resTORbio, Inc., with a date of name change on 20171024.

What is Adicet Bio, Inc.'s SIC code?

Adicet Bio, Inc.'s Standard Industrial Classification (SIC) code is 2834, which corresponds to Pharmaceutical Preparations.

Filing Stats: 1,877 words · 8 min read · ~6 pages · Grade level 14.6 · Accepted 2025-10-07 06:48:42

Key Financial Figures

  • $0.0001 — ch registered Common Stock, par value $0.0001 per share ACET The Nasdaq Global Ma

Filing Documents

01 Other Events

Item 8.01 Other Events. On October 7, 2025, Adicet Bio, Inc. (the Company or Adicet) issued a press release titled "Adicet Bio Announces Positive Preliminary Data from ADI-001 Phase 1 Study in Patients with Lupus Nephritis (LN) and Systemic Lupus Erythematosus (SLE)." A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. Also, on October 7, 2025, the Company will host a webcast to discuss preliminary data from its ADI-001 Phase 1 study in patients with lupus nephritis (LN) and systemic lupus erythematosus (SLE). A copy of the presentation from the webcast will be available on the "Investors" page of the Company's website at www.adicetbio.com and is furnished as Exhibit 99.2 to this Current Report on Form 8-K. The information under this Item 7.01, including Exhibit 99.1 and Exhibit 99.2 hereto, is being furnished herewith and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended (the Securities Act), or the Exchange Act, except as expressly set forth by specific reference in such filing.

01 Other Events

Item 8.01 Other Events. On October 7, 2025, the Company announced preliminary data from its ADI-001 Phase 1 study in patients with LN and SLE. The preliminary data, as well as additional corporate updates, are summarized below. ADI-001 Phase 1 Study Preliminary Data Data highlights as of the August 31, 2025 cut-off date were as follows: Seven patients (five LN and two SLE) were evaluated with follow-up ranging from two to nine months. 100% of patients in the LN cohort achieved renal response, including three complete responses and definition of remission in systemic lupus erythematosus (DORIS) remissions, and two partial responses, with all responses ongoing. 100% of patients saw rapid and sustained reductions in Systemic Lupus Erythematosus Disease Activity Index (SLEDAI-2K) and Physician's Global Assessment (PGA) scores, highlighting ADI-001's potential durable effect on a broad range of lupus symptoms. All patients discontinued immunosuppressants and either discontinued or tapered corticosteroids to physiological levels. ADI-001 demonstrated multiple hallmarks of an immune reset with elimination of dominant B cell clones and subsequent emergence of nave B cells and new B cell repertoire following single dose treatment. As of August 31, 2025, ADI-001 was generally well tolerated and showed a favorable safety profile that could enable dosing in an outpatient setting. o Across all seven patients dosed with ADI-001, there were no serious adverse events, and no reported cases of immune effector cell-associated neurotoxicity syndrome (ICANS). o Two patients experienced Grade 1 cytokine release syndrome (CRS) (fever), and one patient had Grade 1 infection (respiratory tract infection). o There were no cases of Graft-Versus-Host Disease (GvHD), Hemophagocytic Lymphohistiocytosis-Macrophage-Activation Syndrome (HLH-MAS), or prolonged neutropenia. Summary of Phase 1 ADI-001 Preliminary Efficacy Data in LN Patients as of the August 31, 2025 cut-off

Forward-Looking Statements

Forward-Looking Statements The disclosure in this Current Report on Form 8-K contains "forward-looking statements" of Adicet within the meaning of the Private Securities Litigation Reform Act of 1995 relating to the business and operations of Adicet. The words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements include, but are not limited to, express or implied statements regarding Adicet's expectations regarding the clinical development of ADI-001, including the potential safety, tolerability and efficacy of ADI-001 for the treatment of autoimmune diseases; the expected progress, timing and success of the Phase 1 clinical trial of ADI-001 in autoimmune indications, including site activation, continued enrollment and expectations around the timing of future data releases; ADI-001's potential safety profile, availability as an off-the-shelf therapy and outpatient administration; expectations for and timing of future regulatory interactions, including alignment with the FDA for the potential initiation of a Phase 2 pivotal trial for ADI-001; and Adicet's plans for the development of ADI-212, including expected timing for a regulatory filing, enrollment and clinical data. Any forward-looking statements in this Current Report on Form 8-K are based on management's current expectations and beliefs of future events, and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements, including without limitation, the effect of global economic conditions and public health crises on the Company's business and financial results, including with respect to disruptio

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release issued by Adicet Bio, Inc. on October 7, 2025, furnished herewith. 99.2 Corporate presentation of Adicet Bio, Inc., furnished herewith. 99.3 Adicet Bio, Inc. pipeline chart as of October 7, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ADICET BIO, INC. Date: October 7, 2025 By: /s/ Nick Harvey Name: Nick Harvey Title: Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.